Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 11 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and SurgeryCompletedNCT05455632
• Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2
• FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
• 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCCWithdrawnNCT05423197Phase 2
• Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and LungWithdrawnNCT05412875Not applicable
• ITIL-168 in Advanced Solid TumorsWithdrawnNCT05393635Phase 1
• Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2
• A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
• INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnNCT05359692Phase 2
• Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCCStatus unknownNCT05351762Phase 2
• The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCCActive, not recruitingNCT05343325Phase 2
• Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT TrialActive, not recruitingNCT05338905Not applicable
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedNCT05325866Phase 1/2
• A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell CarcinomaTerminatedNCT05322135Early Phase 1
• Safety and Efficacy of APG-157 in Head and Neck CancerActive, not recruitingNCT05312710Phase 2
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1
• Usefulness of Integrated PET/MRI in Oropharyngeal Squamous Cell Carcinoma EvaluationCompletedNCT05299957
• BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)Status unknownNCT05299203Phase 1
• Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell CancerWithdrawnNCT05296135
• IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag GovernorateStatus unknownNCT05293327
• Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and NeckStatus unknownNCT05291663
• DAHANCA 27 Transoral Laser Microsurgery for T1a Glottic CancerStatus unknownNCT05289336Phase 2
• Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical RespondersActive, not recruitingNCT05286294Phase 2
• Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruitingNCT05286060Phase 2
• HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination TherapyActive, not recruitingNCT05280457Phase 2
• Training Swallowing Initiation During ExpirationCompletedNCT05278039Not applicable
• First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
• A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05271604Phase 2
• Develop and Test the 'Multi-Faced Continuous Exercise Program' in Operable Head and Neck Cancer PatientsStatus unknownNCT05267353Not applicable
• A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedNCT05249426Phase 1
• P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05238883Phase 1
• A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWithdrawnNCT05234606Phase 1/2
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsTerminatedNCT05233436Phase 1
• A Study of HFB301001 in Adult Patients With Advanced Solid TumorsTerminatedNCT05229601Phase 1
• Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2
• Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingNCT05222932Phase 1
• RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCCWithdrawnNCT05220748Phase 1
• RTX-224 Monotherapy in Patients With Solid TumorsTerminatedNCT05219578Phase 1/2
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05215574Phase 1
• The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCCCompletedNCT05213884Phase 2
• The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCsStatus unknownNCT05202275Phase 2
• ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck CancerActive, not recruitingNCT05182866Phase 2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCCompletedNCT05156970Phase 2
• Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck CarcinomaActive, not recruitingNCT05156177
• Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass SpectroscopyStatus unknownNCT05150509
• Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2
• Acupuncture for Dysphagia in Head and Neck Squamous Cell CarcinomaStatus unknownNCT05143268
• Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)Status unknownNCT05136768Phase 2
• A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in EuropeCompletedNCT05123950
• Liquid Biopsy of Head and Neck Cancer Patients in Blood and SalivaStatus unknownNCT05122507
• A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)TerminatedNCT05121948Phase 1
• Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell CarcinomaCompletedNCT05119036Not applicable
• Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.CompletedNCT05117775
• Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced TumorsStatus unknownNCT05117138Phase 1/2
• Sleep and Circadian Rhythm Study in Head and Neck Cancer PatientsWithdrawnNCT05099952Not applicable
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersTerminatedNCT05099549Phase 1/2
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
• Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With PembrolizumabStatus unknownNCT05075122Phase 2
• A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)CompletedNCT05068609
• A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
• Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease RecurrenceStatus unknownNCT05065086
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.TerminatedNCT05061940
• A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05054439Phase 2
• Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCCCompletedNCT05053737Phase 1
• Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity CancerCompletedNCT05049408
• A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05044897Phase 2
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2
• PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRTStatus unknownNCT05008796
• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
• Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedNCT04997902Phase 1/2
• Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedNCT04989387Phase 1
• GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer PatientsWithdrawnNCT04987996Phase 2
• Post-treatment Surveillance in HPV+ Oropharyngeal SCCActive, not recruitingNCT04965792
• A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHNCompletedNCT04949503
• Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCCActive, not recruitingNCT04947241Phase 1
• Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging BiomarkersActive, not recruitingNCT04946968Phase 2
• Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersCompletedNCT04943445Phase 2
• Quantifying Systemic Immunosuppression to Personalize Cancer TherapyWithdrawnNCT04941365Not applicable
• Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHNCompletedNCT04939480Phase 2
• Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)Active, not recruitingNCT04938609Phase 2
• Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical TrialStatus unknownNCT04929067Phase 2
• Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell CarcinomaStatus unknownNCT04922450Phase 2
• Sleep Apnea in Head and Neck Cancer Patients at the University of ColoradoWithdrawnNCT04922112Not applicable
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
• A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersWithdrawnNCT04892875Phase 1
• Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.Status unknownNCT04882462Phase 2
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.CompletedNCT04881045Phase 1
• Improving Detection and Early Action for HPV-positive Oropharynx CancerCompletedNCT04871490Not applicable
• Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck CancerCompletedNCT04870840Phase 1
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationActive, not recruitingNCT04868877Phase 1/2
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckCompletedNCT04868162Phase 2
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT04862650Phase 2
• NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerTerminatedNCT04862455Phase 2
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsActive, not recruitingNCT04858269Phase 2
• RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCCWithdrawnNCT04849377Phase 2
• Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaActive, not recruitingNCT04848116Phase 2
• Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT04843098Phase 1/2

← Squamous Cell Carcinoma of Head and Neck overview